Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1Phase 1 1

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Lymphoma, Large B-Cell, Diffuse 6Melanoma 5Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Melanoma × oblimersen × Clear all
NCT01200342 2016-02-11

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled 3 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00016263 2014-01-06

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

National Cancer Institute (NCI)

Phase 3 Completed
Dermatologic

Melanoma

NCT00070343 2014-01-06

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

National Cancer Institute (NCI)

Phase NA Unknown
Dermatologic

Melanoma

NCT00409383 2011-11-07

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Genta Incorporated

Phase 1 Unknown
28 enrolled
Dermatologic

Melanoma

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed
300 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡